ReviewClinical, cosmetic and investigational dermatology2022
Epidemiology and Cutaneous Manifestations of Psoriasis in Saudi Arabia: A Narrative Review.
Review in Clinical, cosmetic and investigational dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Knowledge, Perceptions, and Attitudes Regarding Psoriasis Among the General Population in Jeddah, Saudi Arabia.Cureus · 2026Article
- Analysis of the comprehension and familiarity among the Saudi Arabian population regarding multiple sclerosis.Journal of family medicine and primary care · 2026Article
- Identification and validation of a nomogram for psoriasis diagnosis: a novel biomarker combination with stable high expression in the early stage.Frontiers in medicine · 2026Article
- Stigmatizing Attitudes Toward Persons With Psoriasis in the Western Region of Saudi Arabia.Cureus · 2025Article
- Demographics, Clinical Characteristics, and Treatment Patterns in Patients with Psoriasis: Insights from the Saudi Arabia Psoriasis Registry (PSORSA).Dermatology and therapy · 2025Article
- Prevalence and association of renal disorders in Saudi adult patients with psoriasis and psoriatic arthritis: a tertiary-center retrospective cross-sectional study.Dermatology reports · 2025Article
- Vildagliptin topical ointment: an effective treatment for imiquimod-induced psoriasis in mice.Journal of molecular histology · 2025Article
- The alleviative effects of canagliflozin on imiquimod-induced mouse model of psoriasis-like inflammation.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Association of Psoriasis With Thyroid Disorders: A Tertiary Center-Based Cross-Sectional Study.Cureus · 2025Article
- Mitigative Effects of Topical Norfloxacin on an Imiquimod-Induced Murine Model of Psoriasis.ACS pharmacology & translational science · 2024Article
- Effectiveness of secukinumab in patients with psoriasis and psoriatic arthritis in a Saudi real-world setting.Advances in rheumatology (London, England) · 2024Article
- Prevalence and Causes of Stigmatization Among Patients With Chronic Skin Diseases in Saudi Arabia.Cureus · 2024Article
- The ameliorative effects of topical gemifloxacin alone or in combination with clobetasol propionate on imiquimod-induced model of psoriasis in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Perception and Assessment of Psoriasis Among the General Population in the Jazan Region, Saudi Arabia.Cureus · 2023Article
- Article
- Childhood guttate psoriasis: an updated review.Drugs in context · 2023Review
- Ocular manifestations of psoriasis: An inflammatory disease beyond the skin.Journal of general and family medicine · 2023Article
- Transdermal Permeation Assays of Curcumin Aided by CAGE-IL: In Vivo Control of Psoriasis.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundPsoriasis is an inflammatory immune-mediated illness with an unknown cause. It is a painful, disfiguring, and disabling condition without a complete cure and has enormous negative effects on patients' quality of life. Ethnicity, genetics, and environmental variables all have a role in determining the disease's prevalence. Currently, the large-scale epidemiological studies on cutaneous manifestations of psoriasis in Saudi Arabia are limited.
aimTo evaluate the prevalence of different forms of psoriasis and cutaneous manifestations, pattern, and associated clinical presentation of psoriasis in the Kingdom of Saudi Arabia (KSA). METHODOLOGY: A thorough search of studies on cutaneous manifestations of psoriasis in KSA was conducted from July first 2021 to September 30 2021 using the key phrases "psoriasis," "cutaneous manifestations of psoriasis in KSA," "psoriasis clinical presentation in Saudi Arabia," and "psoriasis skin lesions in Saudi Arabia" at four medical search stations PubMed, Scopus, Google, and Research Gate.
resultsPsoriasis was found to be present in up to 5.33% of the population. More men than women were affected and the age of onset was under 30 years. It was more prevalent in the northern region of KSA. A family history was confirmed in many cases. Plaque psoriasis was the most prevalent kind of psoriasis, followed by guttate psoriasis. Other types of psoriasis, such as pustular psoriasis, erythrodermic psoriasis, follicular psoriasis, inverse psoriasis, and congenital psoriasis, were also found in Saudi patients. There was no evidence of life-threatening psoriasis among Saudis.
conclusionThe major findings of this narrative review revealed plaque-type psoriasis was the most frequent among Saudis followed by guttate psoriasis. Further epidemiological research is needed to better understand the type of cutaneous psoriasis, its impact on the quality of life, and the current therapeutic options which would help advance the national health policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.